Trial reportJournal of ovarian research2026
Intra-ovarian injection of platelet-rich plasma in patients with poor ovarian response; a randomized controlled clinical trial.
Trial report in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Platelet-rich plasma and folliculogenesis: a systematic mechanistic review and computational pathway analysis.Frontiers in reproductive health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere is a clear need for new approaches to help women with low ovarian reserve. A new intervention for women with low ovarian reserve is the intra-ovarian injection of platelet-rich plasma (PRP). It is important to comprehensively evaluate the safety and efficacy of newly introduced treatments before they are used in clinical settings. This randomized controlled clinical trial (RCT) aimed to determine the effect of intra-ovarian PRP injection in patients with a history of poor ovarian response (POR).
methodsIn this RCT were included a total of 200 infertile women from February 2023 to July 2024. Inclusion criteria including infertile women with a history of POR; age < 43 years; body mass index < 35 Kg/m2; follicle-stimulating hormone < 20 IU/mL; anti-mullerian hormone (AMH) < 1.2 ng/mL. The participants were randomly assigned to the two groups with and without Intra-ovarian PRP injection according to a computer-generated, unconcealed randomization list. The primary outcome was an increase in ovarian reserve. All patients were followed for one year.
resultsThere were no significant differences in serum AMH level. The antral follicle count (AFC) was significantly higher in intervention group (p = 0.001). The intervention group demonstrated significantly higher oocyte maturation rate (p = 0.005) and fertilization rate (p = 0.018). The number of high-quality embryos was significantly greater in the intervention group (p = 0.042). In the intervention group, 10.5% of patients achieved spontaneous pregnancy within 3–8 months after intra-ovarian PRP injection. The clinical pregnancy rate following fresh embryo transfer (ET) was significantly higher in the intervention group (p = 0.024). Rates of miscarriage, preterm labor, and pregnancy complications were comparable between groups.
conclusionsOur study demonstrated that the injection of 3 mL PRP with a fivefold platelet concentration compared to baseline serum resulted in increased AFC, reduced ovarian stimulation cancellations, and improved quantitative and qualitative parameters of oocytes and embryos. In addition, intra-ovarian PRP was associated with a considerable rate of spontaneous pregnancy and pregnancy after fresh ET, without significantly increasing rates of pregnancy complications. Despite the strengths of the present study, we still have a rudimentary knowledge of the PRP platform and related elements of this innovative approach. Addressing these shortcomings requires conducting basic studies to resolve the unclear points of this issue.
trial registrationThis study prospectively registered in http://www.Iranian Registry of Clinical Trials.ir (ID: IRCT20080831001141N40) at 01/17/2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.